Gentamicin (n = 44) | Amikacin (n = 35) | ||
---|---|---|---|
Sex | Male | 25 (56.8%) | 23 (65.7%) |
Female | 19 (43.2%) | 12 (34.3%) | |
Status | Preterm (< 37 weeks) | 36 (81.8%) | 24 (68.6%) |
Term | 8 (18.2%) | 11 (31.4%) | |
Gestational age (weeks) | Median (range) | 32 (27–40) | 32 (24–40) |
Postnatal age (days) | Median (range) | 3 (1-14) | 12 (5–25) |
Postmenstrual age (days) | Median (range) | 227 (190–285) | 236 (179–293) |
Birth weighta | Median (range), (g) | 1573 (895–3920) | 1920 (940–4500) |
NBW (≥ 2500 g) | 8 (18.2%) | 9 (25.7%) | |
LBW (< 2500 g) | 19 (43.2%) | 14 (40.0%) | |
VLBW (< 1500 g) | 15 (34.1) | 10 (28.6%) | |
ELBW (1000 g) | 2 (4.5%) | 2 (5.7%) | |
Birth height (cm) | Median (range) | 42 (30–53) | 41 (28–55) |
Body Surface Area (m2) | Median (range) | 0.137 (0.088–0.240) | 0.149 (0.088–0.267) |
eGFR (mL/min/1.73 m2) | Median (range) | 20.3 (8.7–50.4) | 23.2 (10.7–64.9) |
Dose (mg) | Median (range) | 8.0 (4.5–17.0) | 29 (14–62) |
Peak concentration or Cmax (mcg/mL) | Median (range) | 16 (4–64) | 68 (11–260) |
Half-life (h) | 3.8 (1.4–28.0) | 2.4 (0.8–9.5) | |
Drug clearance (L/h) | 0.08 (0.01–1.39) | 0.10 (0.01–1.76) | |
Time to reach toxicity threshold (gentamicin: 1 mcg/mL; amikacin: 5 mcg/mL) (h) | Median (range) | 14.2 (4.3–118.0) | 9.2 (1.1–42.0) |
Duration of therapy (days) | Median (range) | 5 (2–8) | 7 (3–12) |